



## MITHRA AND MEDINER SIGN LSA FOR TIBELIA® IN HUNGARY

- **Mithra grants exclusive license for Tibelia®<sup>1</sup> to Mediner for commercialization in Hungary**
- **Tibelia® is currently marketed in a 8 countries through existing license and supply agreements**
- **Further Tibelia® launches anticipated in 2018**

**Liège, Belgium, 13 July 2018** – Mithra (Euronext Brussels: MITRA), a company dedicated to Women's Health, today announces an exclusive license and supply agreement (LSA) with Mediner for the commercialization of Tibelia® in Hungary.

Tibelia® is a bioequivalent version of Livial® (Merck) developed by Mithra. The product is a synthetic steroid (tibolone) for use in hormone replacement therapy. This includes the relief of postmenopausal symptoms, in addition to prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products. Under the terms of the agreement, Mediner will have the rights to sell the product in Hungary, a market worth approximately EUR 0.6 million<sup>2</sup>.

Mediner is a Hungarian-based company offering a broad portfolio of in-licensed products to its home market, with a key focus on gynecology. With Tibelia®, the company aims to strengthen its position in Women's Health.

Next to license fees, Mithra is eligible for annual revenues over the duration of the 10-year contract.

**François Fornieri, CEO Mithra Women's Health:** *"We are pleased to announce this new agreement for Tibelia®. We expect the product to become an increasingly important source of future revenue, and look forward to additional launches and further partnerships in 2018 and beyond."*

\*\*\*\*\*

---

<sup>1</sup> Tibelia® will be marketed under a different name by Mediner

<sup>2</sup> IMS Health 2017. CAGR in volume (2013-2017): +5%

## About Mediner

Mediner is a private company headquartered in Hungary. The company was founded in 2000. Next to providing marketing and promotional services to healthcare, Mediner also has a broad portfolio of licensed products, with a focus on dermatology, pulmonology and gynecology.

## For more information, please contact:

### Sofie Van Gijssels

IRO & VP of Strategy

+32 485 19 14 15

[investorrelations@mithra.com](mailto:investorrelations@mithra.com)

## About Mithra

Mithra (Euronext: MITRA) is dedicated to providing innovation and choice in women's health, with a particular focus on fertility, contraception and menopause. Mithra's goal is to develop new and improved products that meet women's needs for better safety and convenience. Its two lead development candidates - a fifth generation oral contraceptive, Estelle<sup>®</sup>, and a next generation hormone therapy, Donesta<sup>®</sup>- are built on Mithra's unique natural estrogen platform, E4 (Estetrol). Mithra also develops, manufactures and markets complex therapeutics and offers partners a complete spectrum of research, development and specialist manufacturing at its Mithra CDMO. Mithra was founded in 1999 as a spin-off of the University of Liège by Mr. François Fornieri and Prof. Dr. Jean-Michel Foidart and is headquartered in Liège, Belgium. Further information can be found at: [www.mithra.com](http://www.mithra.com)

## Important information

*The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.*

To subscribe to Mithra's newsletter, visit [investors.mithra.com](http://investors.mithra.com)